Previous Video Next Video

Opioid Receptor Activation and Tolerance (Pain Part 5)

Duration: 53:40

Write A New Comment

2 Comments

kakavand@*.com

Jan 17 2024, 8:55 pm

Please give me the CMEs. Thank you.

mobeen@*.com

Jan 23 2024, 3:40 pm

CMEs are now available.

nas@*.com

Jan 11 2024, 8:06 pm

Interesting video . I have been taking morphine , statex 25mg / 3 hrs for 40 years it gives me a 70% reduction in pain , makes life bearable . Taking more does no good , if I stop taking the pills the pain , very localized becomes unbearable . I HAVE TRIED EVERY therapy NOTHING HAS HELPED

mobeen@*.com

Jan 27 2024, 10:27 pm

Thank you for looking the talk. Working you health!

In this talk we will discuss the following topics:
Opioid receptor structure.
Second messenger system overview.
Desensitization: an immediate effect of opioid use on the receptors and the second messenger system.
Tolerance: days to a week after opioid use disorder the mechanism for sensitization to kick in.
Dependence: a need for opioid use due to severe pains leading to dependence. (See DSM-4 for an exhaustive diagnostic criteria)
Addiction and withdrawal: an addictive state. (See DSM-4 and DSM-5 for an exhaustive diagnostic criteria.)
Opioid receptor disposition.
Adaptation of intracellular signaling mechanism.
System level counteradaptation.
Differential tolerance development.

References:

Effects of Acute and Chronic Opiate Receptor Activation
Brunton, Laurence; Knollman, Bjorn; Hilal-Dandan, Randa. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition (Goodman and Gilman's the Pharmacological Basis of Therapeutics) (p. 1362). McGraw Hill LLC. Kindle Edition.

Receptor specificity of endogenous opioids and effects of receptor activation on neurons.
Brunton, Laurence; Knollman, Bjorn; Hilal-Dandan, Randa. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition (Goodman and Gilman's the Pharmacological Basis of Therapeutics) (p. 1358). McGraw Hill LLC. Kindle Edition.

FDA's recommendations for OUD:
Information about Medication-Assisted Treatment (MAT) | FDA
https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat

Diagnostic criteria for opioid use dependence and opioid use disorder
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder – 2020 Focused Update
https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline?gclid=CjwKCAiAg9urBhB_EiwAgw88mZm1lh6sE-rLtgkJP3w3ij1KSUJ4PkKqNrISFpagDzlQbRitsIJFBhoCQJIQAvD_BwE

npg-jam-supplement.pdf
https://sitefinitystorage.blob.core.windows.net/sitefinity-production-blobs/docs/default-source/guidelines/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2

Psychiatry Online | DSM Legacy
https://dsm.psychiatryonline.org/dsmPreviousEditions

APA_DSM_Changes_from_DSM-IV-TR_-to_DSM-5.pdf
https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM_Changes_from_DSM-IV-TR_-to_DSM-5.pdf

Grasp opioid receptor concepts: desensitization, dependence, addiction, withdrawal.

* Identify μ receptors, understanding desensitization.

* Differentiate tolerance levels specific to opioid actions across organs and systems.

* Understand the effects of opioid withdrawal at the levels of tolerance, dependence, and addiction

. * Summarize DSM-5 criteria for opioid use disorder.

Following answers are created by ChatGPT. Occasionally the answer may be harmful, incorrect, false, misleading, incomplete, or limited in knowledge of world. Please contact your doctor for all healthcare decisions. Also, double check the answer provided by the AI below.

Faculty

In addition to the presenter, following authors may have helped with the content writing, review, or approval:

Dr. Mobeen Syed

CME, CE, CEU and Other Credit Types:

ACCME Accreditation Statement
The DrBeen Corp is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The DrBeen Corp designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information

In accordance with the disclosure policies of DrBeen Corp and the ACCME (Accreditation Council for Continuing Medical Education), we are committed to upholding principles of balance, independence, objectivity, and scientific rigor in all of our Continuing Medical Education (CME) and Continuing Education (CE) activities. These policies include the careful management and mitigation of any relevant financial relationships with organizations that are not eligible.
All members of the Activity Planning Committee and presenters have disclosed their relevant financial relationships. The DrBeen Corp CE Committee has thoroughly reviewed these disclosures and determined that these relationships are not deemed inappropriate in the context of their respective presentations. Additionally, they are found to be consistent with the educational objectives and the integrity of the activity.

Faculty	Disclosures
Dr. Mobeen Syed	Author declares no conflict of interest.

Please login to access this content.

Don't have an account?

Start Your Free trial

No credit card information needed.

Instructors

Dr. Mobeen Syed

MD., MSc., MSc., BSc

Mobeen Syed is the CEO of DrBeen Corp, a modern online medical education marketplace. Mobeen is a medical doctor and a software engineer. He graduated from the prestigious King Edward Medical University Lahore. He has been teaching medicine since 1994. Mobeen is also a software engineer and engineering leader. In this role, Mobeen has run teams consisting of hundreds of engineers and millions of dollars of budgets. Mobeen loves music, teaching, and doing business. He lives in Cupertino CA.